3.2724
price up icon4.65%   0.1524
 
loading
Schlusskurs vom Vortag:
$3.12
Offen:
$3.12
24-Stunden-Volumen:
955.47K
Relative Volume:
0.28
Marktkapitalisierung:
$312.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-84.23M
KGV:
-3.5427
EPS:
-0.9237
Netto-Cashflow:
$-77.15M
1W Leistung:
+14.56%
1M Leistung:
+4.98%
6M Leistung:
-62.94%
1J Leistung:
+29.05%
1-Tages-Spanne:
Value
$3.08
$3.35
1-Wochen-Bereich:
Value
$2.79
$3.35
52-Wochen-Spanne:
Value
$1.07
$11.46

Rezolute Inc Stock (RZLT) Company Profile

Name
Firmenname
Rezolute Inc
Name
Telefon
650-206-4507
Name
Adresse
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Name
Mitarbeiter
71
Name
Twitter
Name
Nächster Verdiensttermin
2025-09-17
Name
Neueste SEC-Einreichungen
Name
RZLT's Discussions on Twitter

Compare RZLT vs VRTX, REGN, ARGX, ALNY, INSM

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
RZLT icon
RZLT
Rezolute Inc
3.27 298.58M 0 -84.23M -77.15M -0.9237
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
433.59 111.45B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
762.90 80.54B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
747.75 46.32B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
330.75 42.29B 3.71B 313.75M 465.38M 2.2571
INSM icon
INSM
Insmed Inc
164.04 35.01B 606.42M -1.28B -997.58M -6.403

Rezolute Inc Stock (RZLT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-03-25 Hochstufung Wedbush Neutral → Outperform
2025-12-11 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-12-11 Herabstufung Craig Hallum Buy → Hold
2025-12-11 Herabstufung Wedbush Outperform → Neutral
2024-11-05 Eingeleitet Wedbush Outperform
2024-08-27 Eingeleitet Guggenheim Buy
2024-07-17 Eingeleitet BTIG Research Buy
2024-06-04 Eingeleitet Craig Hallum Buy
2024-04-09 Eingeleitet Maxim Group Buy
2022-08-02 Fortgesetzt Canaccord Genuity Buy
2022-06-15 Eingeleitet Cantor Fitzgerald Overweight
2021-09-08 Eingeleitet ROTH Capital Buy
2021-05-27 Eingeleitet Oppenheimer Outperform
2021-05-25 Eingeleitet H.C. Wainwright Buy
Alle ansehen

Rezolute Inc Aktie (RZLT) Neueste Nachrichten

pulisher
Apr 04, 2026

RZLT.O PE Ratio & Valuation, Is RZLT.O Overvalued - Intellectia AI

Apr 04, 2026
pulisher
Apr 03, 2026

Rezolute stock gains after FDA meeting on Ersodetug program update - MSN

Apr 03, 2026
pulisher
Apr 02, 2026

Rezolute, Inc. (RZLT) stock price, news, quote and history - Yahoo Finance UK

Apr 02, 2026
pulisher
Apr 02, 2026

RZLT Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 02, 2026
pulisher
Apr 01, 2026

What is HC Wainwright's Estimate for Rezolute Q1 Earnings? - MarketBeat

Apr 01, 2026
pulisher
Mar 31, 2026

Rezolute CFO Evans Daron buys $28,500 in RZLT stock By Investing.com - Investing.com India

Mar 31, 2026
pulisher
Mar 31, 2026

Rezolute CFO Evans Daron buys $28,500 in RZLT stock - investing.com

Mar 31, 2026
pulisher
Mar 31, 2026

Rezolute (RZLT) CFO adds 10,000 shares in open-market purchase - Stock Titan

Mar 31, 2026
pulisher
Mar 31, 2026

RZLT Stock Price, Quote & Chart | REZOLUTE INC (NASDAQ:RZLT) - ChartMill

Mar 31, 2026
pulisher
Mar 30, 2026

Rezolute Inc (RZLT) Stock Price Quote Today & Current Price Chart - Capital.com

Mar 30, 2026
pulisher
Mar 30, 2026

Rezolute Inc (RZLT) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com

Mar 30, 2026
pulisher
Mar 30, 2026

Rezolute: Sell Rating Despite FDA Feedback From Type B Meeting For Ersodetug (NASDAQ:RZLT) - Seeking Alpha

Mar 30, 2026
pulisher
Mar 30, 2026

H.C. Wainwright Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Mar 30, 2026
pulisher
Mar 28, 2026

Will Rezolute Inc outperform during market ralliesTrade Performance Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn

Mar 28, 2026
pulisher
Mar 27, 2026

Rezolute Inc. (RZLT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Mar 27, 2026
pulisher
Mar 27, 2026

Opaleye Management Inc.'s Rezolute Inc(RZLT) Holding History - gurufocus.com

Mar 27, 2026
pulisher
Mar 26, 2026

Volume Report: Will Rezolute Inc stock go up in YEAR2026 Dividend Review & Low Risk High Win Rate Picks - baoquankhu1.vn

Mar 26, 2026
pulisher
Mar 26, 2026

Vanguard realigns reporting; no beneficial stake in Rezolute (RZLT) - Stock Titan

Mar 26, 2026
pulisher
Mar 26, 2026

Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT) - The Globe and Mail

Mar 26, 2026
pulisher
Mar 25, 2026

Rezolute (RZLT) Gains Upgrade Following Positive FDA Meeting - gurufocus.com

Mar 25, 2026
pulisher
Mar 25, 2026

Cantor Fitzgerald Maintains Rezolute(RZLT.US) With Hold Rating - Moomoo

Mar 25, 2026
pulisher
Mar 25, 2026

Rezolute Shares Rise After FDA Signals Hope for Treatment Approval - timothysykes.com

Mar 25, 2026
pulisher
Mar 25, 2026

Rezolute Shares Rise Following FDA Discussion Regarding Ersodetug Program Progress - Bitget

Mar 25, 2026
pulisher
Mar 25, 2026

Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update - The Globe and Mail

Mar 25, 2026
pulisher
Mar 25, 2026

Rezolute’s Shares Soar Despite Initial Obstacles in Trial Data - StocksToTrade

Mar 25, 2026
pulisher
Mar 25, 2026

Wedbush upgrades Rezolute stock rating on FDA feedback By Investing.com - Investing.com Australia

Mar 25, 2026
pulisher
Mar 25, 2026

Citizens reiterates Market Perform on Rezolute stock after FDA update By Investing.com - Investing.com India

Mar 25, 2026
pulisher
Mar 25, 2026

RZLT: Wedbush Upgrades Rezolute with Raised Price Target | RZLT Stock News - GuruFocus

Mar 25, 2026
pulisher
Mar 25, 2026

Rezolute (NASDAQ:RZLT) Stock Rating Upgraded by Wedbush - marketbeat.com

Mar 25, 2026
pulisher
Mar 25, 2026

Cantor Fitzgerald reiterates Neutral on Rezolute stock after FDA meeting By Investing.com - Investing.com Australia

Mar 25, 2026
pulisher
Mar 25, 2026

Cantor Fitzgerald reiterates Neutral on Rezolute stock after FDA meeting - Investing.com

Mar 25, 2026
pulisher
Mar 25, 2026

Rezolute stock maintained at Buy by H.C. Wainwright after FDA meeting - Investing.com Canada

Mar 25, 2026
pulisher
Mar 25, 2026

Wedbush upgrades Rezolute stock rating on FDA feedback - Investing.com

Mar 25, 2026
pulisher
Mar 25, 2026

Wedbush Upgrades Rezolute to Outperform From Neutral, Raises Price Target to $5 From $2 - marketscreener.com

Mar 25, 2026
pulisher
Mar 25, 2026

Citizens reiterates Market Perform on Rezolute stock after FDA update - Investing.com

Mar 25, 2026
pulisher
Mar 25, 2026

FDA Review Puts Rezolute's Genetic Disorder Drug Path In Question - sahmcapital.com

Mar 25, 2026
pulisher
Mar 24, 2026

Energy Moves: Is Rezolute Inc a top pick in the sectorMarket Movement Recap & Weekly Consistent Profit Watchlists - baoquankhu1.vn

Mar 24, 2026
pulisher
Mar 24, 2026

BTIG reiterates Buy on Rezolute stock, keeps $5 target after FDA update - Investing.com India

Mar 24, 2026
pulisher
Mar 24, 2026

BTIG reiterates Buy on Rezolute stock, keeps $5 target after FDA update By Investing.com - Investing.com South Africa

Mar 24, 2026
pulisher
Mar 24, 2026

Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug - BioSpace

Mar 24, 2026
pulisher
Mar 24, 2026

Rezolute Updates on Congenital Hyperinsulinism Program After FDA Meeting; SunRIZE Data Under Review for Potential Advancement 1 - Minichart

Mar 24, 2026
pulisher
Mar 24, 2026

Rezolute (RZLT) Shares Surge After Positive FDA Meeting - gurufocus.com

Mar 24, 2026
pulisher
Mar 24, 2026

Rezolute gains after positive FDA meeting (RZLT:NASDAQ) - Seeking Alpha

Mar 24, 2026
pulisher
Mar 24, 2026

Rezolute to submit sunRIZE trial data to FDA for review By Investing.com - Investing.com Canada

Mar 24, 2026
pulisher
Mar 24, 2026

Rezolute (RZLT) Discusses sunRIZE Study Results with FDA - gurufocus.com

Mar 24, 2026
pulisher
Mar 24, 2026

Rezolute Prepares FDA Submission After sunRIZE Trial Review - tipranks.com

Mar 24, 2026
pulisher
Mar 24, 2026

Rezolute Says It Had Encouraging FDA Meeting on Congenital Hyperinsulinism Drug Despite Missed Endpoint - marketscreener.com

Mar 24, 2026
pulisher
Mar 24, 2026

Rezolute says FDA invited submission of sunRIZE data after Type B meeting; review could inform marketing path - TradingView

Mar 24, 2026
pulisher
Mar 24, 2026

Rezolute to submit sunRIZE trial data to FDA for review - Investing.com

Mar 24, 2026

Finanzdaten der Rezolute Inc-Aktie (RZLT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Rezolute Inc-Aktie (RZLT) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Hogenhuis Wladimir
Director
Dec 16 '25
Buy
1.69
5,650
9,548
119,675
ROBERTS BRIAN KENNETH
Chief Medical Officer
Dec 16 '25
Buy
1.70
28,000
47,600
308,352
Evans Daron
CFO
Dec 15 '25
Buy
1.77
40,000
70,640
415,900
Evans Daron
CFO
Dec 15 '25
Buy
1.79
5,000
8,938
7,000
Elam Nevan C
CEO
Dec 15 '25
Buy
1.59
32,000
50,880
641,119
Karnawat Sunil Ratilal
Chief Commercial Officer
Dec 15 '25
Buy
1.62
12,100
19,599
71,542
ROBERTS BRIAN KENNETH
Chief Medical Officer
Jun 25 '25
Buy
4.38
2,500
10,939
15,500
Evans Daron
CFO
Jun 24 '25
Buy
4.05
5,000
20,250
268,900
Kim Young-Jin
Director
Jun 13 '25
Buy
3.25
1,230,769
3,999,999
8,423,386
KREHER NERISSA
Director
Jun 13 '25
Buy
3.25
3,076
9,997
37,576
$49.55
price down icon 1.90%
$28.34
price up icon 1.08%
$47.79
price down icon 1.05%
$91.15
price up icon 0.08%
ONC ONC
$311.43
price up icon 0.93%
$163.18
price down icon 1.52%
Kapitalisierung:     |  Volumen (24h):